Exicure (XCUR) Competitors $18.67 +2.93 (+18.61%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends XCUR vs. OPT, SLDB, KYTX, GOSS, MDWD, DRUG, HURA, IPHA, CRBP, and SGMTShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Opthea (OPT), Solid Biosciences (SLDB), Kyverna Therapeutics (KYTX), Gossamer Bio (GOSS), MediWound (MDWD), Bright Minds Biosciences (DRUG), TuHURA Biosciences (HURA), Innate Pharma (IPHA), Corbus Pharmaceuticals (CRBP), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Opthea Solid Biosciences Kyverna Therapeutics Gossamer Bio MediWound Bright Minds Biosciences TuHURA Biosciences Innate Pharma Corbus Pharmaceuticals Sagimet Biosciences Opthea (NASDAQ:OPT) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation. Do institutionals and insiders believe in OPT or XCUR? 56.0% of Opthea shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Comparatively, 8.4% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate OPT or XCUR? Opthea presently has a consensus price target of $12.00, indicating a potential upside of 259.28%. Given Opthea's stronger consensus rating and higher probable upside, analysts clearly believe Opthea is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, OPT or XCUR? Exicure has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$124.67K1,564.49-$220.24MN/AN/AExicure$500K97.31-$16.91M-$2.07-9.02 Which has more volatility and risk, OPT or XCUR? Opthea has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.66, meaning that its share price is 266% more volatile than the S&P 500. Does the MarketBeat Community prefer OPT or XCUR? Opthea received 8 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 53.13% of users gave Opthea an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformOptheaOutperform Votes1753.13% Underperform Votes1546.88% ExicureOutperform Votes947.37% Underperform Votes1052.63% Is OPT or XCUR more profitable? Opthea's return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Exicure N/A -190.90%-36.75% Does the media refer more to OPT or XCUR? In the previous week, Opthea had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Opthea and 3 mentions for Exicure. Exicure's average media sentiment score of 0.30 beat Opthea's score of 0.24 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opthea 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOpthea beats Exicure on 11 of the 16 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.65M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-9.0210.5991.3417.19Price / Sales97.31195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book10.675.104.794.78Net Income-$16.91M$151.51M$120.07M$225.60M7 Day Performance7.86%-2.14%-1.90%-1.24%1 Month Performance71.92%-3.13%11.43%3.06%1 Year Performance3,130.10%11.51%30.59%16.50% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure0.8904 of 5 stars$18.67+18.6%N/A+2,901.6%$48.65M$500,000.00-9.0250News CoverageGap UpOPTOpthea2.5742 of 5 stars$3.26+0.3%$12.00+268.1%+31.5%$190.37M$124,666.000.008Analyst UpgradeNews CoverageSLDBSolid Biosciences4.0837 of 5 stars$4.75-3.3%$15.22+220.5%-15.8%$189.81M$8.09M-1.61100KYTXKyverna Therapeutics2.4246 of 5 stars$4.36-1.4%$25.71+489.8%N/A$188.23M$7.03M0.0096News CoverageGOSSGossamer Bio3.622 of 5 stars$0.83-10.7%$9.20+1,007.8%-1.4%$188.20M$105.32M-2.61180MDWDMediWound1.9106 of 5 stars$17.13-0.9%$27.50+60.5%+58.3%$184.76M$19.72M-5.9380Positive NewsGap DownDRUGBright Minds Biosciences3.5821 of 5 stars$40.89-0.3%$75.00+83.4%+2,621.8%$181.31MN/A-60.29N/ANews CoverageHURATuHURA BiosciencesN/A$4.22-14.4%$15.00+255.5%N/A$178.44MN/A0.00N/AAnalyst ForecastNews CoverageIPHAInnate Pharma2.7604 of 5 stars$2.20-27.2%$11.50+422.7%-23.5%$178.13M$24.85M0.00220News CoverageGap DownHigh Trading VolumeCRBPCorbus Pharmaceuticals3.8067 of 5 stars$14.46-4.1%$62.00+328.8%+147.6%$176.12M$880,000.00-3.2240SGMTSagimet Biosciences2.3237 of 5 stars$5.71+30.1%$23.00+302.8%-8.0%$175.13M$2M0.008Gap UpHigh Trading Volume Related Companies and Tools Related Companies Opthea Alternatives Solid Biosciences Alternatives Kyverna Therapeutics Alternatives Gossamer Bio Alternatives MediWound Alternatives Bright Minds Biosciences Alternatives TuHURA Biosciences Alternatives Innate Pharma Alternatives Corbus Pharmaceuticals Alternatives Sagimet Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XCUR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
